Illustrative image – not actual.The Centre has released the Pharmaceutical Policy 2002, which aims at strengthening indigenous drug research, calls for better quality control, ensuring abundant availability of essential drugs and creating a framework for the drug industry which promotes new investment and encourages introduction of new technologies.
The policy includes measures to encourage pharmaceutical research in the country and re-orientation of the pricing system to enable the domestic pharmaceutical industry to meet the challenges and harness opportunities arising from liberalisation of the economy and the advent of the product patent regime in 2005. The policy states that a re-orientation of the existing drug policy, brought out in 1994, has become necessary for improving research incentives so that the industry can achieve sustainable growth even in the new patent regime.
The policy states that indigenous drugs would be kept out of the drug price control mechanism till the patent life of the drug. In the new policy, the span of drug price control would be reduced considerably. The selection criteria would be decided after considering usefulness of various drugs, excluding sera, vaccine and blood products, in different national health programmes along with keeping in mind, the turnover of the drug.
Under the new policy, the government will fix prices of only those bulk drugs whose formulations have an annual turnover of Rs.25 crore and in which a single company making a formulation has a market share of 50 per cent or more. It will also fix prices of formulations with a turnover of Rs.10-25 crore if a single formulator has a market share of 90 per cent or more. The earlier thresholds were Rs.4 crore if any formulator had a market share of 50 per cent or more and Rs.1 crore if any formulator had a market share of 90 per cent or more.
The government has done away with industrial licensing on all bulk drugs, intermediates and formulations cleared by the Drug Controller General of India.
The number of drugs under control has been brought down from 373 in 1979 to 67 in the last two decades.
It may be noted that the introduction of the product patent regime in 2005 would imply that Indian manufacturers would not be allowed to produce drugs, which have been originally developed by some other company.
